- Home
- LBRX vs LE Comparison
LBRX vs LE Comparison
Compare LBRX & LE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBRX | LE |
|---|---|---|
| Founded | 2015 | 1963 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.6M | 550.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LBRX | LE |
|---|---|---|
| Price | $24.14 | $18.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $49.00 | $32.50 |
| AVG Volume (30 Days) | 180.1K | ★ 346.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.55 |
| Revenue Next Year | N/A | $2.38 |
| P/E Ratio | ★ N/A | $48.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.36 | $7.65 |
| 52 Week High | $24.95 | $20.04 |
Technical Indicators
Market Signals| Indicator | LBRX | LE |
|---|---|---|
| Relative Strength Index (RSI) | 58.48 | 57.99 |
| Support Level | $23.52 | $17.15 |
| Resistance Level | $24.84 | $18.62 |
| Average True Range (ATR) | 1.58 | 1.02 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 81.96 | 54.66 |
Price Performance
Historical ComparisonAbout LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
About LE Lands' End Inc.
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically operates in USA, Europe, Asia, it derives a majority of its revenue from the United States.